Investor Lawsuits Mount Against Semler Scientific Over Undisclosed DOJ Probe

Medical technology firm Semler Scientific faces a growing wave of investor litigation following revelations about a long-concealed Department of Justice investigation. The company stands accused of deliberately misleading shareholders about significant regulatory risks, triggering substantial stock declines when the information finally became public.

Central to the controversy is the marketing of Semler’s QuantaFlo technology to Medicare. Federal authorities have been examining potential violations of the False Claims Act since July 2017?a material fact allegedly concealed from investors for years. The company’s annual report, published in late February 2025, contained the first vague reference to these regulatory challenges, immediately sending shares tumbling by 9.4%.

The situation escalated dramatically in April 2025 when Semler reached a settlement agreement with regulators, agreeing... Read more...